AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial
By Elena Vardon
AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across patients with HER2-expressing advanced solid tumours who had been previously treated.
The Anglo-Swedish pharma giant said interim results from its DESTINY-PanTumor02 Phase 2 trial showed an objective response rate of 37.1% in the trial's overall population and also demonstrated positive antitumor activity in patients previously treated for HER2-positive metastatic colorectal cancer.
Enhertu, or trastuzumab deruxtecan, is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 05, 2023 08:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom